       Document 0455
 DOCN  M9620455
 TI    Testicular germ cell tumors and human immunodeficiency virus infection:
       a report of 26 cases. Italian Cooperative Group on AIDS and Tumors.
 DT    9602
 AU    Bernardi D; Salvioni R; Vaccher E; Repetto L; Piersantelli N; Marini B;
       Talamini R; Tirelli U; Division of Medical Oncology and AIDS, Centro di
       Riferimento; Oncologico, Aviano, Italy.
 SO    J Clin Oncol. 1995 Nov;13(11):2705-11. Unique Identifier : AIDSLINE
       MED/96067227
 AB    PURPOSE: Besides tumors that are diagnostic of AIDS, such as
       non-Hodgkin's lymphoma, Kaposi's sarcoma, and invasive carcinoma of the
       cervix, other tumors have been described in the human immunodeficiency
       virus (HIV) setting. Some case reports on testicular cancer in
       HIV-infected patients have appeared in the literature. We present a
       retrospective study on 26 cases of testicular germ cell tumors (TGCTs)
       observed within the Italian Cooperative Group on AIDS and Tumors (GICAT)
       between November 1986 and September 1994. PATIENTS AND METHODS:
       Twenty-six patients with TGCT and HIV-infection from the GICAT were
       retrospectively analyzed. RESULTS: Fourteen patients had seminoma and 12
       had nonseminoma. Four patients underwent only orchidectomy, one patient
       received only chemotherapy, nine patients were treated with postsurgical
       chemotherapy, 10 patients (38%) received postsurgical radiotherapy, one
       patient received postsurgical chemotherapy plus radiotherapy, and one
       patient was lost for follow-up evaluation immediately after diagnosis.
       The complete response (CR) rate was 95%. Relapse occurred in 32% of
       patients. The median follow-up time was 33 months. The mortality rate
       was 37%. Causes of death were neoplasia in three of nine patients, AIDS
       in five of nine patients, and fortuitous event in one of nine patients.
       The overall 3-year survival rate was 65%, and the 3-year disease-free
       survival rate was 65%. Severe hematologic toxicity was observed in seven
       of 15 patients. CONCLUSION: HIV-infected patients with testicular cancer
       should be offered standard oncologic therapy, irrespective of their HIV
       status, since the majority can be cured of their tumor and have a good
       quality of life. Use of concomitant prophylaxis for opportunistic
       infections is recommended.
 DE    Adult  Antineoplastic Agents, Combined/THERAPEUTIC USE  Combined
       Modality Therapy  Disease-Free Survival  Follow-Up Studies
       Germinoma/*ETIOLOGY/MORTALITY/THERAPY  Human  HIV
       Infections/*COMPLICATIONS  Italy  Male  Remission Induction
       Retrospective Studies  Support, Non-U.S. Gov't  Survival Rate
       Testicular Neoplasms/*ETIOLOGY/MORTALITY/THERAPY  JOURNAL ARTICLE
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

